2. Academic Validation
  3. Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia

Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia

  • J Med Chem. 2019 Apr 25;62(8):4218-4224. doi: 10.1021/acs.jmedchem.8b01041.
Yinuo Wu 1,  Qian Zhou 1,  Tianhua Zhang 1,  Zhe Li 1,  Yi-Ping Chen 1,  Pei Zhang 1,  Yan-Fa Yu 1,  Haiju Geng 1,  Yi-Jing Tian 1,  Chen Zhang 1,  Yu Wang 2,  Jian-Wen Chen 1,  Yan Chen 3,  Hai-Bin Luo 1
Affiliations

Affiliations

  • 1 School of Pharmaceutical Sciences , Sun Yat-sen University , Guangzhou 510006 , P. R. China.
  • 2 Infinitus (China) Co. Ltd. , Guangzhou 510663 , P. R. China.
  • 3 College of Pharmaceutical Sciences , Zhejiang University of Technology , Hangzhou 310014 , P. R. China.
PMID: 30916555 DOI: 10.1021/acs.jmedchem.8b01041
Abstract

To identify phosphodiesterase-9 (PDE9) as a novel target for the treatment of vascular dementia (VaD), a series of pyrazolopyrimidinone analogues were discovered based on a hit 1. Hit-to-lead optimization resulted in a potent inhibitor 2 with excellent selectivity and physicochemical properties to enable in vivo studies. Oral administration of 2 (5.0 mg/kg) caused notable therapeutic effects in the VaD mouse model, providing a promising lead or chemical probe for investigating the biological functions of PDE9 inhibition.

Figures
Products